Back to Search Start Over

Dual-Location Dual-Acid/Glutathione-Degradable Cationic Micelleplexes through Hydrophobic Modification for Enhanced Gene Silencing

Authors :
Shetty, Chaitra
Noronha, Anne
Pontarelli, Alexander
Wilds, Christopher J.
Oh, Jung Kwon
Source :
Molecular Pharmaceutics; October 2020, Vol. 17 Issue: 10 p3979-3989, 11p
Publication Year :
2020

Abstract

Gene therapy holds great promise for the treatment of acquired genetic disorders such as cancer with reduced side effects compared to chemotherapy. For gene therapy to be successful, it is crucial to develop efficient and nontoxic gene carriers to overcome the poor in vivostability and low cellular uptake of nucleic acid-based therapeutic agents. Here, we report a new and versatile approach exploring a combination of hydrophobic modifications and dual-stimuli-responsive degradation (SRD) for controlled gene delivery with amphiphilic block copolymer-based nanocarriers. The block copolymer, synthesized by atom transfer radical polymerization, is designed with an acid-labile acetal linkage at the block junction and a pendant disulfide group in the hydrophobic block. The incorporation of labile linkages enables both disulfide-core-cross-linking and dual-location dual-acid/reduction-responsive degradation (DL-DSRD). Furthermore, the disulfide linkages integrated as hydrophobic moieties facilitate the nucleic acids to condense into nanometer-sized micelleplexes through electrostatic interactions of pendant dimethylamino groups with the anionic phosphate groups of the nucleic acids. Our preliminary results demonstrate that the DL-DSRD approach through hydrophobic modification is a robust platform in the development of gene delivery systems with enhanced colloidal stability, reduced cytotoxicity, and improved gene transfection efficiency.

Details

Language :
English
ISSN :
15438384 and 15438392
Volume :
17
Issue :
10
Database :
Supplemental Index
Journal :
Molecular Pharmaceutics
Publication Type :
Periodical
Accession number :
ejs54073105
Full Text :
https://doi.org/10.1021/acs.molpharmaceut.0c00767